VistaGen Therapeutics Sued Over PALISADE‑2 Phase 3 Messaging

Legal Challenge Centers on Phase 3 Messaging

VistaGen Therapeutics faces parallel securities class actions alleging the company mischaracterises the prospects of its fasedienol PALISADE‑2 Phase 3 trial, two U.S. law firms announce. Los Angeles‑based The Schall Law Firm and New York’s DJS Law Group file complaints accusing VistaGen of violating Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b‑5, contending public statements during an April 1, 2024–December 16, 2025 class period create a false impression that the trial was likely to succeed. The suits assert the company downplayed the risk of clinical failure and that investor losses follow the emergence of contrary information.

Both firms are soliciting potential class members and possible lead plaintiffs, emphasising that appointment as lead plaintiff is not required to participate in any recovery. The complaints centre on disclosures and public comments about PALISADE‑2 and fasedienol — VistaGen’s investigational compound for which Phase 3 results are pivotal to regulatory strategy and commercial prospects. Each filing notes that class certification has not occurred and that investors are not represented by counsel until the court designates lead counsel; outcomes could include settlement or trial and will determine any recovery.

VistaGen does not comment in these filings and the litigation introduces a legal and reputational overlay to its clinical development programme. The allegations implicate the company’s investor communications and risk‑disclosure practices at a time when clear messaging is important to relations with regulators, trial partners and potential licensees. The litigation may require management attention and legal resources as the company continues to pursue regulatory pathways for fasedienol.

Lead‑plaintiff deadline and outreach

Both firms set a March 16, 2026 deadline for investors who purchased VistaGen securities during the specified period to register interest in the class actions or seek lead‑plaintiff status, and they offer consultations to evaluate potential losses. The announcements describe their securities litigation practices and note the outreach may constitute attorney advertising in some jurisdictions.

Operational and industry implications

Beyond potential financial exposure, the suits highlight industry scrutiny over how clinical risks and trial prospects are communicated to the market, particularly for small biotech companies where a single Phase 3 programme can determine strategic direction. The cases may prompt heightened governance review and stricter internal controls over clinical disclosures at VistaGen and peer companies.